Association of patient and disease characteristics with outcomes of regorafenib in patients with metastatic colorectal cancer.

被引：0
|
作者：
Hsieh, Ronan Wenhan
Lee, Matthew
Johnson, Devin
Zhang, Chenxin
Moon, Jee-Young
Hsu, Dennis
Acuna-Villaorduna, Ana
Kuang, Chaoyuan
机构：
[1] Univ Pittsbugh, Med Ctr, Pittsburgh, PA USA
[2] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
135
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [1] The impacts of initiating regorafenib with reduced dose on treatment outcomes in metastatic colorectal cancer.
    Kawakami, Takeshi
    Harada, Kazuaki
    Ogata, Takatsugu
    Hu, Qingjiang
    Fushiki, Kunihiro
    Oshima, Kotoe
    Kadowaki, Shigenori
    Taniguchi, Hiroya
    Muro, Kei
    Nakanishi, Ryota
    Ando, Koji
    Nambara, Sho
    Yamamura, Takahiro
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Oki, Eiji
    Masuishi, Toshiki
    Yamazaki, Kentaro
    Yuki, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 133 - 133
  • [2] Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.
    Danilova, Anastasia
    Stroyakovsky, Daniil
    Kanner, Dmitry
    Chernikovksy, Ilya
    Savelov, Nikita
    Volkonsky, Mikhail
    Demidova, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 141 - 141
  • [3] Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer
    Alandag, Celal
    Karaman, Elanur
    Yuce, Elif
    ANTI-CANCER DRUGS, 2022, 33 (04) : 389 - 393
  • [5] PROACTIVE ADVERSE EVENT MANAGEMENT IN REGORAFENIB-TREATED PATIENTS WITH METASTATIC COLORECTAL CANCER.
    Khoukaz, Taline
    Mitchell, Jessica
    ONCOLOGY NURSING FORUM, 2013, 40 (03) : E228 - E228
  • [6] Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC)
    Vogel, A.
    van Cutsem, E.
    Wagner, A.
    Kalmus, J.
    Qin, S.
    Kim, T. W.
    Li, J.
    Xu, R.
    Grothey, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 71 - 71
  • [7] Regorafenib for metastatic Colorectal Cancer?
    Bossenmayer, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (12) : 563 - 563
  • [8] Regorafenib in metastatic colorectal cancer
    Sartore-Bianchi, Andrea
    Zeppellini, Annalisa
    Amatu, Alessio
    Ricotta, Riccardo
    Bencardino, Katia
    Siena, Salvatore
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (03) : 255 - 265
  • [9] Regorafenib for metastatic colorectal cancer
    Ricotta, Riccardo
    Sartore-Bianchi, Andrea
    Verrioli, Antonella
    Vanzulli, Angelo
    Siena, Salvatore
    LANCET, 2013, 381 (9877): : 1537 - 1537
  • [10] Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer.
    Brown, Timothy J.
    Karasic, Thomas Benjamin
    Schneider, Charles John
    Teitelbaum, Ursina R.
    Reiss, Kim Anna
    Mitchell, Tara C.
    Massa, Ryan Campbell
    O'Hara, Mark H.
    DiCicco, Lisa
    Garcia-Marcano, Luis
    Amaravadi, Ravi K.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345